TowerView LLC’s Corvus Pharmaceuticals CRVS Stock Holding History

TowerView LLC’s Portfolio CRVS Stock Details CRVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.05M	Hold	70,000	–	–	0.69%	12
2026 Q1	$1.02M	Sell	70,000 -70,000	-50%	-$1.12M	0.66%	12
2025 Q4	$1.08M	Sell	140,000 -30,000	-18%	-$237K	0.78%	12
2025 Q3	$1.25M	Hold	170,000	–	–	0.91%	13
2025 Q2	$680K	Buy	170,000 +42,500	+33%	+$155K	0.48%	15
2025 Q1	$405K	Buy	127,500 +50,000	+65%	+$236K	0.29%	21
2024 Q4	$415K	Sell	77,500 -40,000	-34%	-$299K	0.3%	19
2024 Q3	$620K	Sell	117,500 -282,500	-71%	-$1.01M	0.4%	17
2024 Q2	$728K	Buy	400,000 +17,500	+5%	+$32.6K	0.48%	17
2024 Q1	$681K	Sell	382,500 -54,373	-12%	-$114K	0.45%	16
2023 Q4	$769K	Buy	436,873 +94,395	+28%	+$138K	0.47%	17
2023 Q3	$500K	Buy	342,478 +137,478	+67%	+$291K	0.33%	18
2023 Q2	$469K	Buy	+205,000	New	+$426K	0.31%	19

Other funds holding CRVS

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

ASP

Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

TowerView LLC's CRVS Position: Q2 2026 in Review

TowerView LLC held its Corvus Pharmaceuticals (CRVS) position steady in Q2 2026 at 70,000 shares worth $1.05M. The position accounts for 0.69% of the portfolio, ranked #12.

TowerView LLC first reported a position in CRVS in Q2 2023 and has held it in 13 quarters since. The position peaked at $1.25M in Q3 2025. 173 funds tracked by Wall St. Rank hold CRVS as of Q2 2026.

TowerView LLC held 70,000 shares of Corvus Pharmaceuticals worth $1.05M as of Q2 2026.
TowerView LLC left its Corvus Pharmaceuticals share count unchanged in Q2 2026.
Corvus Pharmaceuticals made up 0.69% of TowerView LLC's portfolio in Q2 2026, its #12 holding.
TowerView LLC first reported a position in Corvus Pharmaceuticals in Q2 2023 and has held it in 13 quarters since.
TowerView LLC's Corvus Pharmaceuticals position peaked at $1.25M in Q3 2025.
173 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2026.

Based on TowerView LLC's 13F filing for Q2 2026, filed 4 Aug 2026.